Company: BDRX
Filing Date: 2025-12-08
Form Type: F-1/A
Source: 0001214659-25-017719
Chunk: 159

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-08
Form: F-1/A
Chunk 159
---
 insolvency proceedings which may affect
the ability to enforce a judgment. In addition, the United States and the United Kingdom have not currently entered into a treaty (or
convention) providing for the reciprocal recognition and enforcement of judgments (although both are contracting states to the New York
Convention on the Recognition and Enforcement of Foreign Arbitral Awards).

<div align='center'>EXPENSES OF THE OFFERING</div>

The following table sets forth the expenses payable by us in connection
with the sale and distribution of the securities being registered hereby, other than placement agent fees, discounts and commissions.
All amounts shown, other than the SEC registration fee and FINRA filing fee, are estimates:

| SEC registration fee    | $ |  14,231 |
| FINRA filing fee        |   |   3,088 |
| Printing expenses       |   |   5,000 |
| Accounting services     |   |  50,000 |
| Legal fees and expenses |   | 250,000 |
| Miscellaneous           |   |  10,000 |
| Total                   | $ | 332,319 |

| 91 |

<div align='center'>Biodexa Pharmaceuticals PLC

Up to 3,536,345 Units, Each Unit Consisting of One American Depositary Share

and One Series L Warrant to Purchase One American Depositary Share

or

Up to 3,536,345 Pre-Funded Units, Each Pre-Funded Unit Consisting of One Pre-Funded Warrant to Purchase One American Depositary Share

and One Series L Warrant to Purchase One American Depositary Share

Up to 3,536,345 American Depositary Shares Representing 353,634,500,000 Ordinary Shares

Up to 3,536,345 American Depositary Shares Representing 353,634,500,000 Ordinary Shares Underlying the Pre-Funded Warrants

Up to 53,045,175 American Depositary Shares Representing 5,304,517,500,000 Ordinary Shares Underlying the Series L Warrants (which contain a “zero cash exercise price” option)

Up to 2,652,259 American Depositary Shares Representing 265,225,900,000 Underlying the Placement Agent Warrants (which contain a “zero cash exercise price” option)

PRELIMINARY PROSPECTUS

Sole Placement Agent

MAXIM GROUP LLC

, 2025</div>

| 92 |

<div align='center'>PART II